Video

Cholesterol Drugs

Babies in the Womb May Already Be Learning Language

Some Doctors Prescribe Antibiotics Because Parents Want Them

What Kids Wear Could Determine How Much Exercise They Get

Few College Students Have Received the H1N1 Vaccine

Night Lights Could Lead to Depression

Cervarix Has Been Approved by the FDA

The FDA Is Studying the Effects of Lasik Surgery

Painkillers Can Dull the Effects of Childhood Vaccines

Childbirth May Becoming More Complicated

Botox Sponges Might Help Nose Allergies

The FDA Advises on How to Properly Dispose of Medicine

A French Study Shows Cell Phones Do Not Affect Humans

MRIs May Lead to More Back Surgery

Your More Likely to Wash Your Hands If Someone's Watching

Drug Inhibits Colon Cancer in Mice

Posted on 02/12/2009, 09:00
By -- Robert Preidt

Treated with enzastaurin, even tumors that did develop weren't as advanced, study finds

THURSDAY, Feb. 12 (HealthDay News) -- A drug called enzastaurin significantly reduced the development of colon cancer in mice, and tumors that did develop were less advanced and aggressive than those in mice that didn't receive the drug, according to a study by researchers at the Mayo Clinic in Florida.

The findings, coupled with the fact that the drug appears to have minimal side effects, suggest that enzastaurin might offer an effective chemopreventive treatment in people at high risk for colon cancer, the researchers said. The study is to be published in the Feb. 15 issue of the journal Cancer Research.

"There is a need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," senior investigator Nicole Murray, of the department of cancer biology, said in a Mayo news release.

Enzastaurin is designed to suppress signaling through the PKC-beta pathway. In a previous study, the Mayo team found that the pathway is necessary for the start of colon cancer in mice exposed to a carcinogen.

"These mice develop tumors similar to tumors found in humans, but mice without the PKC-beta gene do not," Murray said.

In the new study, the Mayo researchers gave enzastaurin daily to one group of mice and then exposed them, as well as a control group of mice that didn't receive the drug, to a carcinogen that causes colon tumors.

After 22 weeks, 50 percent of the treated mice and 80 percent of the untreated mice had developed tumors. The tumors that did develop in the treated mice were not as advanced as those in the untreated mice.

Enzastaurin is currently being tested to treat a range of human cancers, including B-cell lymphoma and high-grade brain gliomas.

More information

The U.S. National Cancer Institute has more about colon cancer prevention.

SOURCE: Mayo Clinic, news release, Feb. 11, 2009

More news in Lymphoma...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.0 / 5 (112 votes)